Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin^|^ndash;Nicotinamide-Induced Mildly Diabetic Mice
-
- Tahara Atsuo
- Drug Discovery Research, Astellas Pharma, Inc., Japan
-
- Kurosaki Eiji
- Drug Discovery Research, Astellas Pharma, Inc., Japan
-
- Yokono Masanori
- Drug Discovery Research, Astellas Pharma, Inc., Japan
-
- Yamajuku Daisuke
- Drug Discovery Research, Astellas Pharma, Inc., Japan
-
- Kihara Rumi
- Drug Discovery Research, Astellas Pharma, Inc., Japan
-
- Hayashizaki Yuka
- Drug Discovery Research, Astellas Pharma, Inc., Japan
-
- Takasu Toshiyuki
- Drug Discovery Research, Astellas Pharma, Inc., Japan
-
- Imamura Masakazu
- Drug Discovery Research, Astellas Pharma, Inc., Japan
-
- Qun Li
- Applied Pharmacology Research Laboratories, Astellas Pharma Europe B.V., The Netherlands
-
- Tomiyama Hiroshi
- Product Planning and Coordination Division, Research and Development Department, Kotobuki Pharmaceutical Co., Ltd., Japan
-
- Kobayashi Yoshinori
- Synthetic Division, Research Laboratories, Kotobuki Pharmaceutical Co., Ltd., Japan
-
- Noda Atsushi
- Synthetic Division, Research Laboratories, Kotobuki Pharmaceutical Co., Ltd., Japan
-
- Sasamata Masao
- Drug Discovery Research, Astellas Pharma, Inc., Japan
-
- Shibasaki Masayuki
- Drug Discovery Research, Astellas Pharma, Inc., Japan
書誌事項
- タイトル別名
-
- Antidiabetic Effects of SGLT2-Selective Inhibitor Ipragliflozin in Streptozotocin–Nicotinamide-Induced Mildly Diabetic Mice
この論文をさがす
抄録
Sodium-glucose cotransporter (SGLT) 2 plays an important role in renal glucose reabsorption, and inhibition of renal SGLT2 activity represents an innovative strategy for the treatment of hyperglycemia in diabetic patients. The present study investigated the antidiabetic effects of ipragliflozin, a SGLT2-selective inhibitor, in streptozotocin–nicotinamide-induced mildly diabetic mice, which exhibited a mild decline in glucose tolerance associated with the loss of early-phase insulin secretion. Oral administration of ipragliflozin increased urinary glucose excretion in a dose-dependent manner, an effect which was significant at doses of 0.3 mg/kg or higher and lasted over 12 h. In addition, ipragliflozin dose-dependently improved hyperglycemia and glucose intolerance with concomitant decreases in plasma insulin levels without causing hypoglycemia. Once-daily dosing of ipragliflozin (0.1 – 3 mg/kg) for 4 weeks attenuated hyperglycemia, glucose intolerance, and impaired insulin secretion. These results suggest that the SGLT2-selective inhibitor ipragliflozin increases urinary glucose excretion by inhibiting renal glucose reabsorption, improves hyperglycemia in streptozotocin–nicotinamide-induced mildly diabetic mice, and may be useful for treating type 2 diabetes.
収録刊行物
-
- Journal of Pharmacological Sciences
-
Journal of Pharmacological Sciences 120 (1), 36-44, 2012
公益社団法人 日本薬理学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390001205178094720
-
- NII論文ID
- 10031071887
-
- NII書誌ID
- AA11806667
-
- COI
- 1:CAS:528:DC%2BC38XhsVWrs77P
-
- ISSN
- 13478648
- 13478613
-
- NDL書誌ID
- 023957378
-
- PubMed
- 22971845
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可